Methods for inhibiting bone resorption
AssigneeMerck & Co., Inc.
InventorsShun-Ichi Harada, Mohamed Machwate, Gideon A. Rodan, Marc Labelle, Kathleen Metters, Robert N. Young
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods for inhibiting bone resorption in a mammal comprising administering to a mammal in need thereof a therapeutically effective amount of an EP4 receptor subtype antagonist.
Claims22
A method for inhibiting bone resorption in a mammal in need thereof comprising administering to said mammal a therapeutically effective amount of an EP4 receptor subtype antagonist having an EC50 value of from about 0.1 nanoM to about 100 microM.
A method for treating or reducing the risk of contracting a disease state or condition in a mammal in need of such treatment or prevention, comprising administering to said mammal a theraperutically effective amount of an EP4 receptor subtype antagonist.
A method for inhibiting bone resorption in a mammal in need thereof comprising administering to said mammal a therapeutically effective amount of an EP4 receptor subtype antagonist and a bisphosphonate active.
A pharmaceutical composition comprising a therapeutically effective amount of an EP4 receptor subtype antagonist.
A method for identifying a compound which antagonizes an EP4 receptor subtype comprising:
- a). contacting a putative antagonist of an EP4 receptor subtype with a cell culture;
- and
- b). determining the antagonist activity of said putative antagonist with a cell culture not contacted with said putative antagonist.
A method for identifying a compound which antagonizes an EP4 receptor subtype comprising:
- a). contacting a putative antagonist of an EP4 receptor subtype with an EP4 receptor;
- and
- b). determining the antagonist activity of said putative antagonist with an EP4 receptor not contacted with said putative antagonist.
Dependencies are inferred from the claim text.